Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism. This Study Was Previously Registered by the NCRR and Identified as NCRR-M01RR08084-0009

Trial Profile

Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism. This Study Was Previously Registered by the NCRR and Identified as NCRR-M01RR08084-0009

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2015

At a glance

  • Drugs Cholic acid (Primary)
  • Indications Inborn genetic disorders
  • Focus Therapeutic Use
  • Sponsors Asklepion Pharmaceuticals
  • Most Recent Events

    • 17 Mar 2015 According to Asklepion Pharmaceuticals media release, US FDA has approved cholic acid [CHOLBAM] as a once daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects
    • 03 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top